Anyone who is attending the AGM for Shilpa Medicare should look to post the following query to CEO
- In the light of approvals Car-T ( chimeric antigen receptor cell therapy , using one’s own engineered WBC to fight cancerous growth) , what would be the future of anti cancer drugs / therapy. Target date for submissions is 2018 to FDA from Kite Pharma / Novartis & Juno. As you are aware the setback to Juno was because of deaths during toxic side effects. I am sure Mr. Vishnukant would be well informed & he could probably elucidate as to how they see the future for anti cancer drugs.
There is an article on FT this morning about cell therapies-its a good read